Loading...

BioGaia AB (publ)

BIOGY•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$9.75
$-0.40(-3.99%)

BioGaia AB (publ) (BIOGY) Stock Overview

Explore BioGaia AB (publ)’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 73.2/100

Key Financials

Market Cap960.3M
P/E Ratio31.01
EPS (TTM)$0.32
ROE0.18%
Fundamental Analysis

AI Price Forecasts

1 Week$8.14
1 Month$8.55
3 Months$10.08
1 Year Target$11.69

BIOGY Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of BioGaia AB (publ) (BIOGY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 62.54, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $11.69.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 31.01 and a market capitalization of 960.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

62.54RSI (14)
0.14MACD
48.23ADX
Revenue Growth
9.73%
↑ 9.73%
Profit Growth
$3.06
↓ 3.82%
EPS Growth
$3.06
↓ 4.14%
Operating Margin
26.59%
↓ 4.45%
ROE
18.50%
↓ 3.82%
Dividend Yield
0.00%
↑ 137.72%
Analyst Recommendations data is not available for BIOGYAnalyst Recommendations details for BIOGY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through three segments: Pediatrics, Adult Health, and Other. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pylori–the gastric ulcer bacterium; and low bone density. It offers its products under the BioGaia brand name. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.

CEO

Theresa P. Agnew

Employees

224

Headquarters

Kungsbroplan 3, Stockholm

Founded

2021

Frequently Asked Questions

;